Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
UCM05
Cat. No.:
OB0225LY-0030
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
UCM05 is a potent inhibitor of fatty acid synthase (FASN) and inhibitor of filamentous temperature-sensitive protein Z (FtsZ).
Synonym:
G28UCM; 1094451-90-7; 1,3-Bis[(3,4,5-trihydroxybenzoyl)Oxy]Naphthalene; 3-(3,4,5-Trihydroxybenzoyloxy)naphthalen-1-yl 3,4,5-trihydroxybenzoate; [4-(3,4,5-Trihydroxybenzoyl)oxynaphthalen-2-yl] 3,4,5-trihydroxybenzoate
CAS No.:
1094451-90-7
Compound CID:
24896615
Formula:
C24H16O10
Formula Weight:
464.38
Specification
Relative Density:
1.652 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
UCM05 can be used to selectively inhibit the growth of the gram-positive bacterium Bacillus subtilis It can also be used against HER2 drug resistant cell lines.
Library Information
Targets:
Fatty acid synthase
Receptors:
Fatty acid synthase
Pathways:
Metabolism
Plate Number:
AOCL-1
Plate Location:
c11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
90.0 mg/mL; 193.8 mM
